A M Tsimberidou


Affiliation: The University of Texas
Country: USA


  1. Tsimberidou A, Keating M. Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. Leuk Lymphoma. 2010;51:1188-99 pubmed publisher
    ..However, given the diverse mechanisms governing CLL pathogenesis and disease progression, ongoing clinical trials combinations of these agents may improve clinical outcomes for this patient population. ..
  2. Tsimberidou A, Lewis N, Reid T, Burris H, Urban P, Tan E, et al. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;68:1507-16 pubmed publisher
    ..No dose adjustment is required when omeprazole or midazolam is used in patients treated with patupilone. Patupilone exhibited promising antitumor activity in heavily pretreated patients with ovarian and pancreatic cancer. ..
  3. Fountzilas E, Krishnan E, Janku F, Fu S, Karp D, Naing A, et al. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018;: pubmed publisher
    ..9 months (Group 1) and 1.5 and 5.9 months (Group 2). HAI oxaliplatin combined with capecitabine +/- bevacizumab was well-tolerated and was associated with favorable outcomes in selected patients. ..
  4. request reprint
    Tsimberidou A, Giles F, Estey E, O Brien S, Keating M, Kantarjian H. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2006;132:398-409 pubmed
    ..The future of GO is its use in combination with other cytotoxic agents. Ongoing clinical trials may better define the role of GO combinations, particularly in untreated AML. ..
  5. request reprint
    Tsimberidou A, Tirado Gomez M, Andreeff M, O Brien S, Kantarjian H, Keating M, et al. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma. 2006;47:1062-8 pubmed
    ..The observation that patients can be cured of APL without the use of chemotherapy should encourage further study of 'targeted' therapy in APL and in other leukemias. ..
  6. Tsimberidou A, Kantarjian H, Wen S, Keating M, O Brien S, Brandt M, et al. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008;113:1370-8 pubmed publisher
    ..OS analyses yielded similar results. Anti-AML therapy was highly effective in patients with nonleukemic MS. The results from this study emphasize the need to treat patients who have nonleukemic MS with AML-type therapy. ..
  7. Tsimberidou A. Targeted therapy in cancer. Cancer Chemother Pharmacol. 2015;76:1113-32 pubmed publisher
    ..Combinations of targeted, immunomodulating, antiangiogenic, or chemotherapeutic agents are in clinical development. Innovative adaptive study design is used to expedite effective drug development. ..
  8. Tsimberidou A, Wen S, McLaughlin P, O Brien S, Wierda W, Lerner S, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009;27:904-10 pubmed publisher
    ..49). Patients with CLL/SLL have more than twice the risk of developing a second cancer and an increased frequency of certain cancer types. Awareness of risk factors could permit early detection. ..
  9. Wheler J, Yelensky R, Falchook G, Kim K, Hwu P, Tsimberidou A, et al. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer. 2015;15:61 pubmed publisher
    ..A subset of patients with advanced melanoma may harbor only a BRAF mutation and achieve a durable CR on BRAF pathway inhibitors. ..

More Information


  1. Said R, Kakadiaris E, Piha Paul S, Fu S, Falchook G, Janku F, et al. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016;77:1097-102 pubmed publisher
    ..8 and 5.5 months, respectively. The combination of lenalidomide with bevacizumab in patients with advanced solid tumors was safe. Prolonged stable disease was noted in selected tumor types, warranting further clinical evaluation. ..
  2. Tsimberidou A, Iskander N, Hong D, Wheler J, Falchook G, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18:6373-83 pubmed publisher
  3. Said R, Ye Y, Hong D, Naing A, Falchook G, Fu S, et al. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 2016;77:575-81 pubmed publisher
    ..5 months (range <1.6-23), respectively. Lenalidomide in combination with FOLFOX was well tolerated. Four patients had prolonged stable disease. This combination merits further investigation for selected patient populations. ..
  4. Tsimberidou A. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine. Curr Probl Cancer. 2017;41:176-181 pubmed publisher
  5. Liu X, George G, Tsimberidou A, Naing A, Wheler J, Kopetz S, et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015;15:713 pubmed publisher
    ..156). Our data lends support to the concept of clonal evolution, though the clinical impact appears less robust than previously reported. Further work to determine which patients benefit from retreatment post progression is needed. ..
  6. Tsimberidou A, Rudek M, Hong D, Ng C, Blair J, Goldsweig H, et al. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol. 2010;65:235-41 pubmed publisher
    ..This phase I first-in-human trial evaluated salirasib, an S-prenyl derivative of thiosalicylic acid that competitively blocks RAS signaling...